RBC Capital analyst Kennen MacKay said they are buyers of Alexion Pharmaceuticals (NASDAQ: ALXN) on weakness on reports the European ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE